Symbiotec Pharmalab IPO, which was oversubscribed 73.63 times by non-institutional investors, will list on 1 September. The grey market premium is currently +203, indicating a potential listing price above the IPO price of ₹988.Symbiotec Pharmalab IPO, which was oversubscribed 73.63 times by non-institutional investors, will list on 1 September. The grey market premium is currently +203, indicating a potential listing price above the IPO price of ₹988.
Your trusted source for real-time market insights, expert analysis, and breaking financial news. We deliver actionable updates on global markets, stocks, crypto, and economic trends empowering investors to make informed decisions every day.
Contact us: contact@financeworld-news.com
© Copyright 2025 - financeworld-news.com